RxDoctor Payments Data

Diane Sinnatamby, MD

Internal Medicine · Jacksonville, FLNPI 1174575732

Payments from drug & device makers

$631in general payments, 2019–2025

Across 34 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$145
  • Viiv Healthcare Company$144
  • Merck$79
  • Gilead$53
  • AbbVie$36
  • Melinta Therapeutics, LLC$31
  • plus $143 from 7 others

What the payments were for

  • Food & beverage$58392%
  • Education$478%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$631 in reported general payments places this provider in the 60th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$124,438
Medicare patients
292
Services billed
979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala61$248,580
OdefseyEmtricitab/Rilpiviri/Tenof Ala27$98,172
DovatoDolutegravir Sodium/Lamivudine31$93,096
Daptomycin56$89,381
GenvoyaElviteg/Cob/Emtri/Tenof Alafen22$86,124
JulucaDolutegravir/Rilpivirine22$75,737
DescovyEmtricitabine/Tenofov Alafenam31$71,667
TivicayDolutegravir Sodium22$68,669
TriumeqAbacavir/Dolutegravir/Lamivudi15$56,505
IsentressRaltegravir Potassium13$26,098
CeftriaxoneCeftriaxone Sodium116$17,679
Vancomycin Hcl65$15,760
Cefepime Hcl53$13,863
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam53$12,300
Meropenem38$7,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Genvoya, Descovy$53$406,370114 claims
Viiv Healthcare CompanyDovato, Juluca, Tivicay, Triumeq$144$294,00790 claims
MerckIsentress$79$26,09813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →